IsoRay, Inc. (DE) (ISR): Price and Financial Metrics
GET POWR RATINGS... FREE!
ISR POWR Grades
- Sentiment is the dimension where ISR ranks best; there it ranks ahead of 79.23% of US stocks.
- ISR's strongest trending metric is Momentum; it's been moving down over the last 116 days.
- ISR's current lowest rank is in the Quality metric (where it is better than 14.92% of US stocks).
ISR Stock Summary
- ISR's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 9.54% of US stocks.
- In terms of volatility of its share price, ISR is more volatile than 96.06% of stocks we're observing.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for ISR comes in at -48.89% -- higher than that of merely 4.68% of stocks in our set.
- Stocks that are quantitatively similar to ISR, based on their financial statements, market capitalization, and price volatility, are ASTC, UAMY, MSON, CRWS, and BAND.
- Visit ISR's SEC page to see the company's official filings. To visit the company's web site, go to www.isoray.com.
ISR Stock Price Chart Interactive Chart >
ISR Price/Volume Stats
|Current price||$0.82||52-week high||$2.81|
|Prev. close||$0.82||52-week low||$0.35|
|Day high||$0.83||Avg. volume||9,471,602|
|50-day MA||$0.87||Dividend yield||N/A|
|200-day MA||$0.91||Market Cap||115.52M|
IsoRay, Inc. (DE) (ISR) Company Bio
Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma. It sells its products to facilities or physician practices that utilize multiple surgical facilities at which primarily prostate brachytherapy procedures are performed. Isoray, Inc. was founded in 1998 and is headquartered in Richland, Washington.
ISR Latest News Stream
|Loading, please wait...|
ISR Latest Social Stream
View Full ISR Social Stream
Latest ISR News From Around the Web
Below are the latest news stories about Isoray Inc that investors may wish to consider to help them evaluate ISR as an investment opportunity.
IsoRay (ISR) delivered earnings and revenue surprises of 0.00% and 6.56%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Revenue Increased 10% Sequentially Record Non-Prostate Brachytherapy Revenue Increased 20% Year-Over-Year RICHLAND, Wash., May 13, 2021 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced its financial results for the third quarter fiscal 2021 ended March 31, 2021. Revenue for the third quarter of fiscal 2021 declined 10% to $2.60 million versus the record $2.88 million in the prior year comparable period. Revenue increased 10% sequentially from the fiscal second quarter ended December 31,2020. The company’s core prostate brachytherapy revenue declined 16% versus the record third quarter of fiscal 2020 as procedure volumes continued to be impacted...
NEW YORK, NY / ACCESSWIRE / May 13, 2021 / IsoRay, Inc. (AMEX:ISR) will be discussing their earnings results in their 2021 Third Quarter Earnings call to be held on May 13, 2021 at 4:30 PM Eastern Time.
According to a recently published small pilot study of patients with recurrent head and neck cancers treated with surgical resection and IsoRay Inc's (NYSE: ISR), Cesium-131 brachytherapy showed potential benefits that could support further research into combination therapy. This study's primary findings include the fact that re-treatment of recurrent head and neck cancers with surgical resection and Cesium-131 brachytherapy appears safe and feasible. Study authors noted that brachytherapy provides the possibility of optimal dose conformity with sharp dose fall-off that limits radiation dose to normal tissues, leading to fewer side effects compared to external beam radiation therapy. It was also noted that brachytherapy performed at the time of surgery is convenient for patients who wou...
University Hospitals Cleveland Medical Center Pilot Study Shows Promise for High-Risk Recurrent Head and Neck Cancer Treatment with Cesium-131 and Surgical Resection
RICHLAND, Wash., March 31, 2021 (GLOBE NEWSWIRE) -- A recently published small prospective series of patients with recurrent head and neck (H&N) cancers treated with surgical resection and Isoray’s Cesium-131 brachytherapy found potential benefits that support further research into combination therapy with Cesium-131 brachytherapy and surgical resection. The prospective series was conducted at the University Hospitals Cleveland Medical Center and involved 12 patients who were consented to an IRB-approved protocol that began accruing patients in 2016. The research team was led by Dr. Min Yao, Department of Radiation Oncology, and Dr. Chad Zender, Department of Otolaryngology Head and Neck Surgery, University Hospitals Cleveland Medical Center. Yao is also a professor in the radiology dep...
ISR Price Returns